• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.050 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 563,222
Open 1.080
Bid (Size) 1.030 (100)
Ask (Size) 1.140 (2,700)
Prev. Close 1.050
Today's Range 1.030 - 1.100
52wk Range 0.7615 - 2.100
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
October 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
September 30, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

52-Week Range 50.0% below 52-week high
1.050
0.7652W Low 2.1052W High
1 Week 12.5% below 1-week high
1.021W Low 1.201W High

Tiziana Life Sciences Ltd - Common Shares (TLSA) traded between $0.76 and $2.10 over the past 52 weeks and last traded at $1.05, 50.0% below its 52-week high. Over the past week it ranged between $1.02 and $1.20.

Past 12 Months
-3.7%
+15.9%
+3.4%
-13.2%
-34.4%
-46.4%
1W -$0.04
1M +$0.14
3M +$0.04
6M -$0.16
YTD -$0.55
1Y -$0.91

TLSA was -46.4% over the past year, -13.2% over six months, -34.4% year to date, -3.7% in the last week.

12 Months vs Market
TLSA
-46.4%
DIA
+11.2%
SPY
+13.7%
QQQ
+16.1%
IWM
+9.0%

Over the past 12 months TLSA returned -46.4% versus DIA (Dow) +11.2%, SPY (S&P 500) +13.7%, QQQ (Nasdaq 100) +16.1% and IWM (Russell 2000) +9.0%.

Volume & Liquidity 0.74× 3-mo avg
Today 563,222 3-mo avg 765.4K
1W
493.9K
1M
687.5K
3M
765.4K
6M
497.1K
YTD
388.6K
1Y
369.6K

TLSA most recently traded 563,222 shares against a 3-month average daily volume of 765.4K.

More News

Read More
News headline image
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
September 28, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
September 21, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
September 17, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
August 24, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
August 06, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
August 04, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
July 31, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
July 22, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
June 25, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman
June 15, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗
May 29, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York
May 28, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial
May 21, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
May 19, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab
May 14, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
April 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress
April 14, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging
April 01, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA
February 25, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
January 20, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
January 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
January 16, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
January 09, 2026
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
What is the current price of Tiziana Life Sciences Ltd - Common Shares?
The current price of Tiziana Life Sciences Ltd - Common Shares is 1.050
When was Tiziana Life Sciences Ltd - Common Shares last traded?
The last trade of Tiziana Life Sciences Ltd - Common Shares was at 10/16/26 04:00 PM ET
What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 204.34M
How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
Tiziana Life Sciences Ltd - Common Shares has 204M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap